The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should patients with high pre-transplant serum Claudin-3 be treated differently?

Dec 12, 2019

The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Shernan Holtan, University of Minnesota, Minneapolis, US, was based on the question: Should patients with high pre-transplant serum Claudin-3 be treated differently to reduce the risk of graft-versus-host disease?

Shernan Holtan explains that patients who have a high level of serum Claudin-3 before transplant have a higher risk of both gastro-intestinal GvHD (GI-GvHD) and non-relapse mortality (NRM). She explains her research showed that Claudin-3 was the only biomarker that successfully predicted the risk of GI-GvHD and NRM in pre-transplant patients, and discussed its future implications in the clinic.

Should patients with high pre-transplant serum Claudin-3 be treated differently?